Metronidazol B. Braun

Metronidazole, the active ingredient in Metronidazol B. Braun, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It treats anaerobic bacterial and protozoal infections in adult patients.

GNH USA supplies Metronidazol B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide.

Metronidazole is used to treat infections caused by anaerobic bacteria and certain protozoa.

- Anaerobic bacterial infections: effective in eliminating susceptible anaerobic organisms and controlling infection. - Trichomoniasis: eradicates the protozoan parasite causing vaginal infection. - Giardiasis: clears intestinal infection caused by Giardia lamblia. - Intra‑abdominal infections: helps resolve polymicrobial infections following surgery or perforation. - Pelvic inflammatory disease: contributes to treatment of mixed aerobic‑anaerobic pelvic infections.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Metallic taste - Headache - Dizziness - Abdominal discomfort - Diarrhea

Serious or Rare Side Effects: - Seizures - Peripheral neuropathy - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome - Liver toxicity - Neutropenia

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

- Renal impairment: adjust therapy based on clinical judgment. - Hepatic dysfunction: monitor liver enzymes during treatment. - Alcohol consumption: avoid during and at least 48 hours after therapy due to disulfiram‑like reaction. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Concurrent CNS depressants: monitor for additive central nervous system effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metronidazole interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: increased anticoagulant effect, monitor INR. - Lithium: risk of toxicity, monitor serum levels. - Cimetidine: may raise metronidazole concentrations. - Phenobarbital: may reduce metronidazole efficacy.

Moderate Interactions (Monitor Closely): - Erythromycin: possible increased neurotoxicity. - Bupropion: heightened seizure risk. - Carbamazepine: may decrease metronidazole levels. - Theophylline: monitor for enhanced side effects. - Oral contraceptives: may reduce effectiveness, advise backup method.